MA50800A - Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson - Google Patents

Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson

Info

Publication number
MA50800A
MA50800A MA050800A MA50800A MA50800A MA 50800 A MA50800 A MA 50800A MA 050800 A MA050800 A MA 050800A MA 50800 A MA50800 A MA 50800A MA 50800 A MA50800 A MA 50800A
Authority
MA
Morocco
Prior art keywords
catecholamine
parkinson
disease
treatment
new
Prior art date
Application number
MA050800A
Other languages
English (en)
Inventor
Klaus Gjervig Jensen
Martin Juhl
Lisbet Kværnø
Jørgensen Morten
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA50800A publication Critical patent/MA50800A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050800A 2017-11-24 2018-11-23 Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson MA50800A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201700674 2017-11-24

Publications (1)

Publication Number Publication Date
MA50800A true MA50800A (fr) 2020-09-30

Family

ID=64661284

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050800A MA50800A (fr) 2017-11-24 2018-11-23 Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson

Country Status (25)

Country Link
US (5) US10729710B2 (fr)
EP (1) EP3713933B1 (fr)
JP (4) JP7320507B2 (fr)
KR (1) KR102712887B1 (fr)
CN (3) CN117653649A (fr)
AR (1) AR113908A1 (fr)
AU (2) AU2018371193B2 (fr)
BR (1) BR112019014981A2 (fr)
CA (1) CA3082757A1 (fr)
CL (1) CL2020001343A1 (fr)
CO (1) CO2020006224A2 (fr)
CR (1) CR20200225A (fr)
EA (1) EA202090987A8 (fr)
EC (1) ECSP20030074A (fr)
GE (2) GEAP202215342A (fr)
IL (1) IL274648B2 (fr)
JO (2) JOP20200114B1 (fr)
MA (1) MA50800A (fr)
MX (2) MX2020005366A (fr)
PE (1) PE20211290A1 (fr)
PH (1) PH12020550631A1 (fr)
SG (1) SG11202004461YA (fr)
TW (1) TWI816716B (fr)
UA (1) UA127575C2 (fr)
WO (1) WO2019101917A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200225A (es) * 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) * 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
WO2020234276A1 (fr) * 2019-05-21 2020-11-26 H. Lundbeck A/S Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
EP3972971A1 (fr) 2019-05-21 2022-03-30 H. Lundbeck A/S Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de maladies de parkinson
WO2020234277A1 (fr) 2019-05-21 2020-11-26 H. Lundbeck A/S Promédicaments de carbamate de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
JP7641234B2 (ja) * 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP4247793A1 (fr) * 2020-11-17 2023-09-27 H. Lundbeck A/S Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
WO2023208867A1 (fr) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab Nouveaux composés de 1,2,3,4,4a,5,8,9,10,10a-décahydrobenzo[g]quinolin-6(7h)-one et leurs utilisations
IL316452A (en) 2022-04-25 2024-12-01 Integrative Res Laboratories Sweden Ab New esters of 1,2,3,4,4a,5,6,7,8,9,10,10a-dodecahydrobenzo[g]quinolin-6-ol compounds and their uses
US20250282733A1 (en) 2022-04-25 2025-09-11 Integrative Research Laboratories Sweden Ab Novel 1,2,3,4,4a,5,6,7,8,9,10,10a-dodecahydrobenzo[g]quinolin-6-ol compounds and uses thereof
KR20250023394A (ko) 2022-06-15 2025-02-18 에버 뉴로 파르마 게엠베하 아포모르핀 전구약물 및 이의 용도
WO2025078574A1 (fr) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab Nouveaux esters de composés 1,2,3,4,4a,5,6,7,8,9,10,10a-dodécahydrobenzo[g]quinolin-6-ol et leurs utilisations
WO2025078571A1 (fr) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab Nouveaux carbonates et carbamates de composés 1,2,3,4,4a,5,6,7,8,9,10,10a-dodécahydrobenzo[g]quinolin-6-ol et leurs utilisations

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
DE19575006I2 (de) 1981-10-16 2003-01-09 Novartis Ag 1, 2, 3, 4a, 5, 10, 10a-Octahydrobenzo(g)chinolin-Derivate mit pharmazeutischer Wirkung
FR2540112B1 (fr) 1983-02-01 1986-08-29 Sandoz Sa Nouveaux derives de la benzo(g)quinoleine, leur preparation et leur utilisation comme medicaments
JPS60172975A (ja) 1984-02-15 1985-09-06 Sumitomo Chem Co Ltd エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en) 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ES2070994T3 (es) 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
WO1990012574A1 (fr) 1989-04-25 1990-11-01 Northeastern University Composes agonistes de la dopamine
IT1271411B (it) 1993-09-14 1997-05-28 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en) 1993-12-21 1999-09-21 Sandoz Ltd. Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
IT1289979B1 (it) 1997-02-26 1998-10-19 Zambon Spa 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
GB9902938D0 (en) 1999-02-10 1999-03-31 Novartis Ag Organic compounds
CO5261532A1 (es) 1999-11-15 2003-03-31 Novartis Ag Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
MXPA02009904A (es) 2000-04-07 2004-09-06 Tap Pharmaceutical Prod Inc Derivados de apomorfina y metodos para su uso.
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
KR20030027020A (ko) 2000-08-11 2003-04-03 펄듀 리서치 파운데이션 디나프솔린의 제조 공정
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PE20030240A1 (es) 2001-07-09 2003-04-16 Novartis Ag DERIVADOS DE BENZO [g] QUINOLINA
DE60220800D1 (de) 2001-08-10 2007-08-02 Purdue Research Foundation Chirales dinapsolin
EG24415A (en) 2002-03-07 2009-05-25 Novartis Ag Quinoline derivatives
CA2479372A1 (fr) 2002-03-19 2003-10-02 Michael Holick Derives de glycoside et de glycoside orthoester d'apomorphine, d'analogues et utilisations correspondantes
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US20070155720A1 (en) 2003-12-23 2007-07-05 Darpharma, Inc. Co-administration of dopamine-receptor binding compounds
WO2006012640A2 (fr) 2004-07-21 2006-02-02 Darpharma, Inc. Procedes d'administration d'agonistes du recepteur de la dopamine
WO2006056604A1 (fr) 2004-11-25 2006-06-01 Evolva Ag Derives de levodopa glycosyl, procedes de preparation et d'utilisation associes
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TWI404702B (zh) 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
CN102131790A (zh) 2008-06-27 2011-07-20 H.隆德贝克有限公司 新型苯酚型和儿茶酚型胺及其前药
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
TW201035054A (en) 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
EP2557079A1 (fr) 2011-08-09 2013-02-13 Nestec S.A. Synthèse de catéchine et conjugués d'épicatéchine
DE102011112496A1 (de) 2011-09-07 2013-03-07 Thanares GmbH 4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh) 2012-07-23 2018-03-02 上海弈柯莱生物医药科技有限公司 灯盏花乙素及其类似物的制备方法
GB201319768D0 (en) 2013-11-08 2013-12-25 Glycosynth Ltd Naphthalene derived chromogenic enzyme substrates
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
CN105218606B (zh) 2015-10-19 2017-12-01 昆明理工大学 一种制备灯盏乙素的方法
EP4295909A3 (fr) 2016-04-20 2024-07-17 AbbVie Inc. Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation
US9920342B2 (en) 2016-05-17 2018-03-20 Divi's Laboratories Limited Process for the preparation of Droxidopa
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
WO2020234277A1 (fr) 2019-05-21 2020-11-26 H. Lundbeck A/S Promédicaments de carbamate de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
EP3972971A1 (fr) 2019-05-21 2022-03-30 H. Lundbeck A/S Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de maladies de parkinson
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2020234276A1 (fr) 2019-05-21 2020-11-26 H. Lundbeck A/S Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
EP4247793A1 (fr) 2020-11-17 2023-09-27 H. Lundbeck A/S Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
JP7693430B2 (ja) * 2021-07-15 2025-06-17 株式会社日立製作所 運行提案システム、及び運行提案作成方法

Also Published As

Publication number Publication date
BR112019014981A2 (pt) 2020-04-07
CN111386267B (zh) 2023-12-12
CR20200225A (es) 2020-07-25
KR102712887B1 (ko) 2024-10-02
RU2020116419A (ru) 2021-12-27
US20240156851A1 (en) 2024-05-16
PH12020550631A1 (en) 2021-02-22
US20200338102A1 (en) 2020-10-29
US11110110B2 (en) 2021-09-07
US10729710B2 (en) 2020-08-04
UA127575C2 (uk) 2023-10-18
EA202090987A8 (ru) 2020-09-29
JP2021504345A (ja) 2021-02-15
CN117653649A (zh) 2024-03-08
TWI816716B (zh) 2023-10-01
AU2018371193A1 (en) 2020-06-11
IL274648B1 (en) 2024-06-01
US12226428B2 (en) 2025-02-18
EP3713933B1 (fr) 2026-03-25
CA3082757A1 (fr) 2019-05-31
JOP20230235A1 (ar) 2023-09-26
CN111386267A (zh) 2020-07-07
JP2023055830A (ja) 2023-04-18
AR113908A1 (es) 2020-06-24
MX2022016276A (es) 2023-02-09
IL274648B2 (en) 2024-10-01
JP7443606B2 (ja) 2024-03-05
GEP20227446B (en) 2022-12-12
JOP20200114B1 (ar) 2024-04-18
US20250381208A1 (en) 2025-12-18
ECSP20030074A (es) 2020-07-31
CN117599073A (zh) 2024-02-27
GEAP202215342A (en) 2022-07-11
AU2018371193B2 (en) 2022-12-22
SG11202004461YA (en) 2020-06-29
AU2023201741A1 (en) 2023-04-20
CO2020006224A2 (es) 2020-05-29
JP2023145580A (ja) 2023-10-11
EA202090987A1 (ru) 2020-08-07
US20190160083A1 (en) 2019-05-30
IL274648A (en) 2020-06-30
JP7320684B2 (ja) 2023-08-03
JOP20200114A1 (ar) 2020-05-17
TW201924693A (zh) 2019-07-01
US11707476B2 (en) 2023-07-25
JP2023145579A (ja) 2023-10-11
JP7320507B2 (ja) 2023-08-03
MX2020005366A (es) 2020-08-13
KR20200092955A (ko) 2020-08-04
EP3713933A1 (fr) 2020-09-30
CL2020001343A1 (es) 2020-09-25
US20220257623A1 (en) 2022-08-18
NZ764717A (en) 2024-08-30
WO2019101917A1 (fr) 2019-05-31
PE20211290A1 (es) 2021-07-20

Similar Documents

Publication Publication Date Title
MA50800A (fr) Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
MA49402A (fr) Polynucléotides aadc pour le traitement de la maladie de parkinson
EP3405215A4 (fr) Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie
EP3706755A4 (fr) Ganaxolone destinée à être utilisée dans le traitement de troubles épileptiques génétiques
EP3820537A4 (fr) Vecteurs de thérapie génique pour le traitement de la maladie de danon
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA54792A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3592841A4 (fr) Procédés et compositions de traitement de cancers à l'aide d'acides nucléiques antisens
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
EP3600304A4 (fr) Alcaloïdes berbérine dans la prévention et/ou le traitement d'une maladie intestinale
EP3490436A4 (fr) Procédés de détection et de traitement de la douleur à l'aide de l'activité cérébrale
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
MA50233A (fr) Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
HUE059387T2 (hu) Parkinson-kór kezelése
EP3694579A4 (fr) Administration automatisée à base clinique de substances de traitement à l'oreille interne
EP3362096A4 (fr) Composition de traitement ophtalmique et véhicule pour l'administration de substances pharmaceutiques ou d'agents thérapeutiques
EP3856168A4 (fr) Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés
EP3833435A4 (fr) Détermination de la maladie de parkinson
EP4069700A4 (fr) Macrocycles destinés à être utilisés dans le traitement d'une maladie
EP3654961A4 (fr) Méthodes et compositions pour le traitement de la douleur à l'aide de la capsaïcine
EP3398614A4 (fr) Agent pour la prévention et/ou le traitement de la maladie d'alzheimer
EP3802568A4 (fr) Agents thérapeutiques peptidiques pour le traitement de la maladie d'alzheimer et d'états apparentés
EP3628008A4 (fr) Compositions et méthodes pour le traitement de la maladie d'alzheimer
EP3852722A4 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson